Nuvectis Pharma Statistics
Share Statistics
Nuvectis Pharma has 23.39M
shares outstanding. The number of shares has increased by 27.43%
in one year.
| Shares Outstanding | 23.39M |
| Shares Change (YoY) | 27.43% |
| Shares Change (QoQ) | 21.07% |
| Owned by Institutions (%) | 7.67% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 3,678 |
| FTD / Avg. Volume | 2.7% |
Short Selling Information
The latest short interest is 1.63M, so 6.98% of the outstanding
shares have been sold short.
| Short Interest | 1.63M |
| Short % of Shares Out | 6.98% |
| Short % of Float | 11.48% |
| Short Ratio (days to cover) | 15.07 |
Valuation Ratios
The PE ratio is -4.87 and the forward
PE ratio is -8.91.
Nuvectis Pharma's PEG ratio is
0.22.
| PE Ratio | -4.87 |
| Forward PE | -8.91 |
| PS Ratio | 0 |
| Forward PS | 1.7 |
| PB Ratio | 9.53 |
| P/FCF Ratio | -7.56 |
| PEG Ratio | 0.22 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Nuvectis Pharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.09,
with a Debt / Equity ratio of 0.
| Current Ratio | 2.09 |
| Quick Ratio | 2.09 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,461,538.46 |
| Employee Count | 13 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 12.65% in the
last 52 weeks. The beta is -0.12, so Nuvectis Pharma's
price volatility has been lower than the market average.
| Beta | -0.12 |
| 52-Week Price Change | 12.65% |
| 50-Day Moving Average | 8.66 |
| 200-Day Moving Average | 6.99 |
| Relative Strength Index (RSI) | 49.15 |
| Average Volume (20 Days) | 136,027 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -19.85M |
| Net Income | -19M |
| EBITDA | -19M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.11 |
Full Income StatementBalance Sheet
The company has 18.53M in cash and 0 in
debt, giving a net cash position of 18.53M.
| Cash & Cash Equivalents | 18.53M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -73.25M |
| Total Assets | 18.61M |
| Working Capital | 9.71M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -12.25M
and capital expenditures 0, giving a free cash flow of -12.25M.
| Operating Cash Flow | -12.25M |
| Capital Expenditures | n/a |
| Free Cash Flow | -12.25M |
| FCF Per Share | -0.72 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
